AgingResearch.NewsJoin free

BCN Peptides

CompanySpain

BCN Peptides develops one asset, in phase 2, no development reported (somatostatin in diabetic retinopathy). Mostly peptide acting on SSTR2, SSTR4 and SSTR5; based in Spain.

1
Asset
Furthest stage
Phase 2, no development reported
1
Trial
5
Signals

Pipeline

1

  • somatostatin

    Activates somatostatin receptors to protect retinal neurons and reduce retinal vascular dysfunction.

    Phase 2, no development reported, Peptide, SSTR2, SSTR4, diabetic retinopathy

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms4
  • Trials1
  • Signals20
  • Similar companies6

Intelligence